By Josh White
Date: Monday 25 Mar 2024
(Sharecast News) - Monoclonal antibody specialist BioVentix reported a 13% rise in first-half revenue on Monday, to £6.7m, compared to £5.9m in the prior year.
By Alexander Bueso
Date: Sunday 19 Nov 2023
(Sharecast News) - The Financial Mail on Sunday's Midas column tipped the Octopus Renewables Infrastructure Trust to readers, pointing out its 7% dividend yield and the current valuation of its shares.
By Josh White
Date: Monday 24 Oct 2022
(Sharecast News) - Diagnostic monoclonal antibody specialist BioVentix reported a 7% improvement in revenue in its full-year results on Monday, to £11.72m.
Currency | UK Pounds |
Share Price | 4,471.43p |
Change Today | -53.57p |
% Change | -1.18 % |
52 Week High | 5,060.00 |
52 Week Low | 3,500.00 |
Volume | 937 |
Shares Issued | 5.22m |
Market Cap | £233.39m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Latest | Previous | |
---|---|---|
1st Interim | 2nd Interim | |
Ex-Div | 11-Apr-24 | 09-Nov-23 |
Paid | 26-Apr-24 | 24-Nov-23 |
Amount | 68.00p | 90.00p |
Time | Volume / Share Price |
14:26 | 100 @ 4,485.00p |
14:16 | 245 @ 4,487.00p |
14:00 | 340 @ 4,489.00p |
13:19 | 1 @ 4,452.50p |
11:20 | 1 @ 4,592.50p |
CEO | Peter John Harrison |
Chair | Ian James Nicholson |
CFO | Bruce Hiscock |
You are here: research